Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer

Drug Metabolism and Pharmacokinetics

Volumn 27, Issue 3, 2012, Pages 325-335

  Akiyama, Yuko ^a   Fujita, Ken Ichi ^a   Ishida, Hiroo ^a   Sunakawa, Yu ^a   Yamashita, Keishi ^a   Kawara, Kaori ^a   Miwa, Keisuke ^a   Saji, Shigehira ^a   Sasaki, Yasutsuna ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

ABCC2; Colorectal cancer; Efficacy; FOLFIRI; Irinotecan; Japanese

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C2; FIRTECAN; FIRTECAN GLUCURONIDE; FLUOROURACIL; FOLINIC ACID; GENOMIC DNA; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; COLORECTAL CANCER; DNA SEQUENCE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HAPLOTYPE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY;

EID: 84863199899     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-11-RG-128     Document Type: Article

References (41)

1. Kudoh, S., Fujiwara, Y., Takada, Y., Yamamoto, H., Kinoshita, A., Ariyoshi, Y., Furuse, K. and Fukuoka, M.: Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J. Clin. Oncol., 16: 1068-1074 (1998).
2. Negoro, S., Fukuoka, M., Masuda, N., Takada, M., Kusunoki, Y., Matsui, K., Takifuji, N., Kudoh, S., Niitani, H. and Taguchi, T.: Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J. Natl. Cancer Inst., 83: 1164-1168 (1991).
3. Rougier, P., Van Cutsem, E., Bajetta, E., Niederle, N., Possinger, K., Labianca, R., Navarro, M., Morant, R., Bleiberg, H., Wils, J., Awad, L., Herait, P. and Jacques, C: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet, 352: 1407-1412 (1998).
4. Sparreboom, A., Fujita, K. and Zamboni, W. C: Topoisomerase I-Targeting Drugs. In Chabner, B. A. and Longo, D. L. (eds.): Cancer Chemotherapy and Biotherapy Principles and Practice, Philadelphia: Lippincott Williams & Wilkins, 2010, pp. 342-355.
5. Nozawa, T., Minami, H., Sugiura, S., Tsuji, A. and Tamai, I.: Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycampto-thecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab. Dispos., 33: 434-439 (2005).
6. Chu, X. Y., Kato, Y., Niinuma, K., Sudo, K. I., Hakusui, H. and Sugiyama, Y.: Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J. Pharmacol. Exp. Ther., 281: 304-314 (1997).
7. Iyer, L., Ramirez, J., Shepard, D. R., Bingham, C. M., Hossfeld, D. K., Ratain, M. J. and Mayer, U.: Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice. Cancer Chemother. Pharmacol., 49: 336-341 (2002).
8. Nakatomi, K., Yoshikawa, M., Oka, M., Ikegami, Y., Hayasaka, S., Sano, K., Shiozawa, K., Kawabata, S., Soda, H., Ishikawa, T., Tanabe, S. and Kohno, S.: Transport of 7-ethyl-10-hydroxycamp-tothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem. Biophys. Res. Commun., 288: 827-832 (2001).
9. Han, J. Y., Lim, H. S., Shin, E. S., Yoo, Y. K., Park, Y. H., Lee, J. E., Jang, I. J., Lee, D. H. and Lee, J. S.: Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J. Clin. Oncol., 24: 2237-2244 (2006).
10. Minami, H., Sai, K., Saeki, M., Saito, Y., Ozawa, S., Suzuki, K., Kaniwa, N., Sawada, J., Hamaguchi, T., Yamamoto, N., Shirao, K., Yamada, Y., Ohmatsu, H., Kubota, K., Yoshida, T., Ohtsu, A. and Saijo, N.: Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet. Genomics, 17: 497-504 (2007).
11. Cecchin, E., Innocenti, F., D'Andrea, M., Corona, G., De Mattia, E., Biason, P., Buonadonna, A. and Toffoli, G.: Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J. Clin. Oncol., 27: 2457-2465 (2009).
12. Toffoli, G., Cecchin, E., Corona, G., Russo, A., Buonadonna, A., D'Andrea, M., Pasetto, L. M., Pessa, S., Errante, D., De Pangher, V., Giusto, M., Medici, M., Gaion, F., Sandri, P., Galligioni, E., Bonura, S., Boccalon, M., Biason, P. and Frustaci, S.: The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J. Clin. Oncol., 24: 3061-3068 (2006).
13. Beretta, G. L., Cossa, G., Gatti, L., Zunino, F. and Perego, P.: Tyrosyl-DNA phosphodiesterase 1 targeting for modulation of camptothecin-based treatment. Curr. Med. Chem., 17: 1500-1508 (2010).
14. Hu, Z., Ma, H., Lu, D., Zhou, J., Chen, Y., Xu, L., Zhu, J., Huo, X., Qian, J., Wei, Q. and Shen, H.: A promoter polymorphism (-77T>C) of DNA repair gene XRCC1 is associated with risk of lung cancer in relation to tobacco smoking. Pharmacogenet. Genomics, 15: 457-463 (2005).
15. Park, S. Y., Lam, W. and Cheng, Y. C: X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance. Cancer Res., 62: 459-465 (2002).
16. Rasheed, Z. A. and Rubin, E. H.: Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene, 22: 7296-7304 (2003).
17. Han, J. Y., Lee, G. K., Yoo, S. Y., Yoon, S. J., Cho, E. Y., Kim, H. T. and Lee, J. S.: Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy. Pharmacogenomics J., 10: 86-93 (2010).
18. Douillard, J. Y., Cunningham, D., Roth, A. D., Navarro, M., James, R. D., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., Gruia, G., Awad, L. and Rougier, P.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet, 355: 1041-1047 (2000).
19. Sunakawa, Y., Ichikawa, W., Fujita, K., Nagashima, F., Ishida, H., Yamashita, K., Mizuno, K., Miwa, K., Kawara, K., Akiyama, Y., Araki, K., Yamamoto, W., Miya, T., Narabayashi, M., Ando, Y., Hirose, T., Saji, S. and Sasaki, Y.: UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer. Cancer Chemother. Pharmacol., 68: 279-284 (2011).
20. Fujita, K., Ando, Y., Nagashima, F., Yamamoto, W., Eodo, H., Araki, K., Kodama, K., Miya, T., Narabayashi, M. and Sasaki, Y.: Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer. Cancer Chemother. Pharmacol., 60: 515-522 (2007).
21. Fujita, K., Nagashima, F., Yamamoto, W., Endo, H., Sunakawa, Y., Yamashita, K., Ishida, H., Mizuno, K., Matsunaga, M., Araki, K., Tanaka, R., Ichikawa, W., Miya, T., Narabayashi, M., Akiyama, Y., Kawara, K., Ando, Y. and Sasaki, Y.: Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI). Biol. Pharm. Bull., 31: 2137-2142 (2008).
22. Kiyotani, K., Mushiroda, T., Imamura, C. K., Hosono, N., Tsunoda, T., Kubo, M., Tanigawara, Y., Flockhart, D. A., Desta, Z., Skaar, T. C, Aki, F., Hirata, K., Takatsuka, Y., Okazaki, M., Ohsumi, S., Yamakawa, T., Sasa, M., Nakamura, Y. and Zembutsu, H.: Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients.J. Clin. Oncol., 28: 1287-1293 (2010).
23. Kiyotani, K., Mushiroda, T., Kubo, M., Zembutsu, H., Sugiyama, Y. and Nakamura, Y.: Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci., 99: 967-972 (2008).
24. Fujita, K., Ando, Y., Yamamoto, W., Miya, T., Endo, H., Sunakawa, Y., Araki, K., Kodama, K., Nagashima, F., Ichikawa, W., Narabayashi, M., Akiyama, Y., Kawara, K., Shiomi, M., Ogata, H., Iwasa, H., Okazaki, Y., Hirose, T. and Sasaki, Y.: Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer. Cancer Chemother. Pharmacol, 65: 251-258 (2010).
25. Maekawa, K., Itoda, M., Sai, K., Saito, Y., Kaniwa, N., Shirao, K., Hamaguchi, T., Kunitoh, H., Yamamoto, N., Tamura, T., Minami, H., Kubota, K., Ohtsu, A., Yoshida, T., Saijo, N., Kamatani, N., Ozawa, S. and Sawada, J.: Genetic variation and haplotype structure of the ABC transporter gene ABCG2 in a Japanese population. Drug Metab. Pharmacokinet., 21: 109-121 (2006).
26. Kim, S. R., Saito, Y., Sai, K., Kurose, K., Maekawa, K., Kaniwa, N., Ozawa, S., Kamatani, N., Shirao, K., Yamamoto, N., Hamaguchi, T., Kunitoh, H., Ohe, Y., Yamada, Y., Tamura, T., Yoshida, T., Minami, H., Ohtsu, A., Saijo, N. and Sawada, J.: Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than *15. Drug Metab. Pharmacokinet., 22: 456-461 (2007).
27. Hoskins, J. M., Marcuello, E., Altes, A., Marsh, S., Maxwell, T., Van Booven, D. J., Pare, L., Culverhouse, R., McLeod, H. L. and Baiget, M.: Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clin. Cancer Res., 14: 1788-1796 (2008).
28. Hoskins, J. M., Rosner, G. L., Ratain, M. J., McLeod, H. L. and Innocenti, F.: Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan. Pharmacogenomics, 10: 1139-1146 (2009).
29. Cao, W. H., Wang, X., Frappart, L., Rigal, D., Wang, Z. Q., Shen, Y. and Tong, W. M.: Analysis of genetic variants of the poly(ADP-ribose) polymerase-1 gene in breast cancer in French patients. Mutat. Res., 632: 20-28 (2007).
30. Zhang, X., Miao, X., Liang, G., Hao, B., Wang, Y., Tan, W., Li, Y., Guo, Y., He, F., Wei, Q. and Lin, D.: Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. Cancer Res., 65: 722-726 (2005).
31. Wang, Y., Spitz, M. R., Zhu, Y., Dong, Q., Shete, S. and Wu, X.: From genotype to phenotype: correlating XRCC1 polymorphisms with mutagen sensitivity. DNA Repair (Amst.), 2: 901-908 (2003).
32. Han, J. Y., Lim, H. S., Yoo, Y. K., Shin, E. S., Park, Y. H., Lee, S. Y., Lee, J. E., Lee, D. H., Kim, H. T. and Lee, J. S.: Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer, 110: 138-147 (2007).
33. Sun, N., Sun, X., Chen, B., Cheng, H., Feng, J., Cheng, L. and Lu, Z.: MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother. Pharmacol., 65: 437-446 (2010).
34. Han, B., Gao, G., Wu, W., Gao, Z., Zhao, X., Li, L., Qiao, R., Chen, H., Wei, Q., Wu, J. and Lu, D.: Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients. Lung Cancer, 72: 238-243 (2011).
35. Haenisch, S., Zimmermann, U., Dazert, E., Wruck, C. J., Dazert, P., Siegmund, W., Kroemer, H. K., Warzok, R. W. and Cascorbi, I.: Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J., 7: 56-65 (2007).
36. Haenisch, S., May, K., Wegner, D., Caliebe, A., Cascorbi, I. and Siegmund, W.: Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol. Pharmacogenet. Genomics, 18: 357-365 (2008).
37. Zhang, Y., Zhao, T., Li, W. and Vore, M.: The 5-untranslated region of multidrug resistance associated protein 2 (MRP2; ABCC2) regulates downstream open reading frame expression through translational regulation. Mol. Pharmacol., 77: 237-246 (2010).
38. Innocenti, F., Kroetz, D. L., Schuetz, E., Dolan, M. E., Ramirez, J., Relling, M., Chen, P., Das, S., Rosner, G. L. and Ratain, M. J.: Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J. Clin. Oncol., 27: 2604-2614 (2009).
39. Taniguchi, K., Wada, M., Kohno, K., Nakamura, T., Kawabe, T., Kawakami, M., Kagotani, K., Okumura, K., Akiyama, S. and Kuwano, M.: A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res., 56: 4124-4129 (1996).
40. Kusuhara, H., Han, Y. H., Shimoda, M., Kokue, E., Suzuki, H. and Sugiyama, Y.: Reduced folate derivatives are endogenous substrates for cMOAT in rats. Am. J. Physiol., 275: G789-G796 (1998).
41. Han, J. Y., Lim, H. S., Shin, E. S., Yoo, Y. K., Park, Y. H., Lee, J. E., Kim, H. T. and Lee, J. S.: Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer, 59:69-75 (2008).